Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $1,428,991.83 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83. Following the sale, the insider directly owned 25,249 shares of the company’s stock, valued at approximately $843,064.11. This trade represents a 62.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.49, for a total value of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.47, for a total value of $619,298.13.

Eton Pharmaceuticals Trading Down 4.4%

Shares of NASDAQ:ETON opened at $30.45 on Friday. Eton Pharmaceuticals, Inc. has a 12-month low of $13.09 and a 12-month high of $35.66. The business’s fifty day simple moving average is $27.08 and its 200-day simple moving average is $20.21. The company has a market capitalization of $834.09 million, a PE ratio of -434.94 and a beta of 0.82. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The company had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $22.31 million. As a group, equities research analysts predict that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current fiscal year.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Opaleye Management Inc. lifted its position in Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after acquiring an additional 7,930 shares during the period. EcoR1 Capital LLC lifted its position in Eton Pharmaceuticals by 7.0% during the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after acquiring an additional 141,394 shares during the period. Vanguard Group Inc. lifted its position in Eton Pharmaceuticals by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock worth $29,208,000 after acquiring an additional 31,942 shares during the period. State Street Corp lifted its position in Eton Pharmaceuticals by 14.5% during the 4th quarter. State Street Corp now owns 501,925 shares of the company’s stock worth $8,488,000 after acquiring an additional 63,480 shares during the period. Finally, Cannell Capital LLC boosted its holdings in Eton Pharmaceuticals by 17.3% in the third quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock valued at $9,896,000 after purchasing an additional 67,230 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HC Wainwright lifted their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a report on Friday, May 15th. Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. B. Riley Financial upped their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Craig Hallum upped their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Finally, Zacks Research lowered Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $41.00.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.